Chemoprophylaxis of Fungal Infections in Granulocytopenic Patients Using Fluconazole vs Oral Amphotericin B

Drug Investigation

Volumn 3, Issue 4, 1991, Pages 258-265

  Meunier, F ^a,b   Aoun, M ^a   Janssens, M ^a   Dekoster, C ^a   Paesmans, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; CANCER; CANDIDIASIS; CLINICAL ARTICLE; FEMALE; GRANULOCYTOPENIA; HUMAN; MALE; MYCOSIS; ORAL DRUG ADMINISTRATION; TRICHOSPORON;

EID: 0025949490     PISSN: 01142402     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/BF03259575     Document Type: Article

References (29)

1. New spectrum of fungal infections in patients with cancer
2. Effect of prophylactic measures on the microbial flora of patients in protected environment units
3. Incidence of polyene-resistant yeasts recovered from clinical specimens
4. Fatal disseminated candidiasis due to amphotericin B resistant Candida guillermondii
5. Candida species
6. Fatal septicemia due to amphotericin B-resistant Candida lusitaniae
7. Colonization and infection with Trichosporon species in the immunosuppressed host
8. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans
9. Invasive infections due to Candida krusei: report of 10 cases of fungemia including 3 cases of endophthalmitis
10. Candida lusitaniae. frequency of recovery, colonization, infection and amphotericin B resistance
11. Diagnosis and successful treatment of fusariosis in the compromised host
12. Increased incidence of fungemia caused by Candida krusei
13. Prevention of mycoses in immunocompromised patients
14. Fungal infections in the compromised host
15. Chemoprophylaxis of fungal infections
16. Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients
17. Fungemia in the immunocompromised host: changing patterns, antigenemia, high mortality
18. Development of resistance to amphotericin B in Candida lusitaniae infection in a human
19. Efficacy of fluconazole in experimental aspergillosis
20. Amphotericin B-resistant yeast infection in severely immunocompromised patients
21. Azole antifungal agents: emphasis on new triazoles
22. Prophylaxis of oropharyngeal candidiasis with fluconazole
23. The value of fungal surveillance cultures as predictors of systemic fungal infections
24. Surveillance cultures
25. Infection prevention in acute non lymphocytic leukemia
26. Origin of infection in acute non lymphocytic leukemia. Significance of hospital acquisition of potential pathogens
27. Interaction of fluconazole and cyclosporine
28. Ketoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies
29. Trichosporin beigelii and emerging pathogen resistant to amphotericin B